SERB Pharmaceuticals to acquire Aurlumyn from CiVi Biopharma.

SERB Pharmaceuticals, a global specialty pharmaceutical company with a growing portfolio of medicines for emergency care and rare diseases, agreed to acquire Aurlumyn, a FDA approved treatment option for severe frostbite in the US, from CiVi Biopharma, a pharmaceutical company. Financial terms were not disclosed. “Aurlumyn™ is set to become a gold standard treatment for frostbite, a rare yet debilitating condition, making it an ideal addition to our broad and diverse emergency care portfolio. This acquisition expands our leadership in rare emergency medicines and is a perfect fit for our US commercial capabilities,” Arthur Pignot, SERB Chief Strategy Officer.